Advance discovery, innovation, and increase the likelihood of trial success with real-world clinical and molecular data, including DNA, RNA and whole slide pathology images.
Contact UsLeverage real-world multimodal data and bioinformatics expertise to identify disease subtypes and power discovery approaches to lead to novel therapeutic opportunities
Read case studyAnalyze your target of interest and identify the most appropriate patient population to evaluate for your therapy program
Read case studyDesign trials, validate biomarker strategies, define optimal populations to study and assess execution feasibility. Plus, conduct trial simulation and survival analysis to support trial success
Tempus Lens is a comprehensive, real-world, multi-modal data platform that enables Life Science companies to leverage a self-service model to uncover new insights across the research and development spectrum to make smarter decisions and launch molecules more efficiently.
Tempus establishes joint research teams combining disciplines from computational biology, medical, bioinformatics, and machine learning to work alongside your teams with a goal of accelerating therapy development.
Tempus bioinformatics experts help you answer your oncology research questions and meet your research objectives efficiently
Our data licensing partnership provides you with access to de-identified multi-modal data to support iterative research and development objectives using the tools you are most comfortable with
2/3 of the top 20
oncology pharma companies*
120+
biopharma companies
5M+
de-identified research records to power scientific discovery
1M+
records with imaging data
500K+
with matched clinical and molecular data to understand driver mutations and outcomes associations
100K+
with full transcriptomic data for interrogating tumor biology and mechanisms of action
20x larger
database than the Cancer Genome Atlas, which we believe to be the largest public genomic database, based on petabytes of data
Tempus signs strategic collaboration agreement with AstraZeneca to advance oncology therapeutics
Read press releaseTempus announces agreement with Janssen R&D to leverage AI/ML and real-world evidence to enhance the discovery and development of oncology therapies
Read press releaseUsing molecular signatures of Pancreatic Ductal Adenocarcinoma (PDAC) for targeting discovery
Read case studyPairing sequencing, analytics, and data licensing to uncover new R&D insights
Read case studiesOther Solutions for Life Sciences